Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation
2017-001604-30Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clazakizumab in Antibody-mediated kidney allograft rejection (AMR), sponsored by Medical University of Vienna. Primary endpoint: Safety and tolerability of clazakizumab. Started Sep 2017; status: completed.
02
Drugs
clazakizumab
03
Conditions
Antibody-mediated kidney allograft rejection (AMR)
Beyond the preview
Go deeper on 2017-001604-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001604-30.